Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Capital Expenditures (2024 - 2025)

Caris Life Sciences has reported Capital Expenditures over the past 2 years, most recently at -$8.7 million for Q4 2025.

  • Quarterly results put Capital Expenditures at -$8.7 million for Q4 2025, down 112.63% from a year ago — trailing twelve months through Dec 2025 was -$3.9 million (changed N/A YoY), and the annual figure for FY2025 was $2.4 million, up 19.3%.
  • Capital Expenditures for Q4 2025 was -$8.7 million at Caris Life Sciences, down from $7.1 million in the prior quarter.
  • Over the last five years, Capital Expenditures for CAI hit a ceiling of $7.1 million in Q3 2025 and a floor of -$8.7 million in Q4 2025.